Levetiracetam Arrow Lab (Levetiracetam)

Levetiracetam exerts its effect by binding to the synaptic vesicle protein SV2A, which regulates neurotransmitter release. This binding modulates vesicle exocytosis, stabilizing neuronal firing and decreasing hyper‑excitability, thereby lowering the likelihood of the synchronized neuronal discharges that cause seizures.

The dosage of levetiracetam is individualized. A prescriber determines the appropriate amount based on the patient’s age, weight, renal function, seizure type, and response to therapy. Starting doses and titration schedules are tailored to achieve optimal seizure control while minimizing adverse effects.

Data on levetiracetam use in pregnancy and lactation are limited. Clinicians weigh the potential benefits against unknown risks, and the drug is generally prescribed only when the therapeutic advantage outweighs possible fetal or infant exposure. Breastfeeding mothers should discuss potential exposure with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with older agents such as valproate or carbamazepine, levetiracetam has a more favorable drug‑interaction profile, fewer enzyme‑inducing effects, and a generally simpler titration schedule. However, individual response varies, and clinicians consider seizure type, comorbidities, and tolerability when selecting therapy.

Levetiracetam Arrow Lab tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain product stability.

Levetiracetam is taken orally, typically as a tablet that should be swallowed whole with or without food. The exact administration schedule—once, twice, or three times daily—is determined by the prescribing clinician based on the patient’s therapeutic needs.

Serious adverse events, although rare, include severe allergic reactions such as Stevens‑Johnson syndrome, significant psychiatric changes like depression or suicidal thoughts, and hematologic abnormalities such as neutropenia or thrombocytopenia. Patients should be monitored closely for any of these symptoms.

Levetiracetam is contraindicated in individuals with a known hypersensitivity to the drug or any of its components. Patients with severe renal impairment require dose adjustment; without appropriate modification, use may be unsafe. Clinicians should also exercise caution in patients with a history of psychiatric disorders.